FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022878833> ?p ?o ?g. }

• W2022878833 endingPage "1097" @default.
• W2022878833 startingPage "1089" @default.
• W2022878833 abstract "To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD).Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fixed dosing period. Data were analyzed to week 16.We included 159 patients with subfoveal choroidal neovascularization secondary to wet AMD.Patients were randomized 1:1:1:1:1 to VEGF Trap-Eye during the fixed-dosing phase (day 1 to week 12): 0.5 or 2 mg every 4 weeks (0.5 mg q4wk, 2 mg q4wk) on day 1 and at weeks 4, 8, and 12; or 0.5, 2, or 4 mg every 12 weeks (0.5 mg q12wk, 2 mg q12wk, or 4 mg q12wk) on day 1 and at week 12.The primary endpoint was change from baseline in central retinal/lesion thickness (CR/LT) at week 12; secondary outcomes included change in best-corrected visual acuity (BCVA), proportion of patients with a gain of ≥ 15 letters, proportion of patients with a loss of >15 letters, and safety.At week 12, treatment with VEGF Trap-Eye resulted in a significant mean decrease in CR/LT of 119 μm from baseline in all groups combined (P<0.0001). The reduction in CR/LT with the 2 mg q4wk and 0.5mg q4wk regimens was significantly greater than each of the quarterly dosing regimens. The BCVA increased significantly by a mean of 5.7 letters at 12 weeks in the combined group (P<0.0001), with the greatest mean gain of >8 letters in the monthly dosing groups. At 8 weeks, BCVA improvements were similar with 2 mg q4wk and 2 mg q12wk dosing. After the last required dose at week 12, CR/LT and visual acuity were maintained or further improved at week 16 in all treatment groups. Ocular adverse events were mild and consistent with safety profiles reported for other intraocular anti-VEGF treatments.Repeated monthly intravitreal dosing of VEGF Trap-Eye over 12 weeks demonstrated significant reductions in retinal thickness and improvements in visual acuity, and was well-tolerated in patients with neovascular AMD.Proprietary or commercial disclosure may be found after the references." @default.
• W2022878833 created "2016-06-24" @default.
• W2022878833 creator A5001427765 @default.
• W2022878833 creator A5002669383 @default.
• W2022878833 creator A5028848967 @default.
• W2022878833 creator A5030449236 @default.
• W2022878833 creator A5036246396 @default.
• W2022878833 creator A5056613332 @default.
• W2022878833 creator A5061673504 @default.
• W2022878833 creator A5068758746 @default.
• W2022878833 creator A5072551893 @default.
• W2022878833 creator A5083524146 @default.
• W2022878833 creator A5085672493 @default.
• W2022878833 creator A5091022089 @default.
• W2022878833 date "2011-06-01" @default.
• W2022878833 modified "2023-10-15" @default.
• W2022878833 title "Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration" @default.
• W2022878833 cites W1487528435 @default.
• W2022878833 cites W1875554126 @default.
• W2022878833 cites W1980725734 @default.
• W2022878833 cites W1996870435 @default.
• W2022878833 cites W2003586642 @default.
• W2022878833 cites W2019061836 @default.
• W2022878833 cites W2029406931 @default.
• W2022878833 cites W2035353185 @default.
• W2022878833 cites W2051842051 @default.
• W2022878833 cites W2059889603 @default.
• W2022878833 cites W2069826874 @default.
• W2022878833 cites W2075634939 @default.
• W2022878833 cites W2077595741 @default.
• W2022878833 cites W2085712747 @default.
• W2022878833 cites W2090248679 @default.
• W2022878833 cites W2091774189 @default.
• W2022878833 cites W2098155102 @default.
• W2022878833 cites W2101247829 @default.
• W2022878833 cites W2118548020 @default.
• W2022878833 cites W2120822810 @default.
• W2022878833 cites W2124415048 @default.
• W2022878833 cites W2143874967 @default.
• W2022878833 cites W2148994564 @default.
• W2022878833 cites W2154711032 @default.
• W2022878833 cites W2081847856 @default.
• W2022878833 doi "https://doi.org/10.1016/j.ophtha.2011.02.039" @default.
• W2022878833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21640257" @default.
• W2022878833 hasPublicationYear "2011" @default.
• W2022878833 type Work @default.
• W2022878833 sameAs 2022878833 @default.
• W2022878833 citedByCount "91" @default.
• W2022878833 countsByYear W20228788332012 @default.
• W2022878833 countsByYear W20228788332013 @default.
• W2022878833 countsByYear W20228788332014 @default.
• W2022878833 countsByYear W20228788332015 @default.
• W2022878833 countsByYear W20228788332016 @default.
• W2022878833 countsByYear W20228788332017 @default.
• W2022878833 countsByYear W20228788332018 @default.
• W2022878833 countsByYear W20228788332019 @default.
• W2022878833 countsByYear W20228788332020 @default.
• W2022878833 countsByYear W20228788332021 @default.
• W2022878833 countsByYear W20228788332022 @default.
• W2022878833 countsByYear W20228788332023 @default.
• W2022878833 crossrefType "journal-article" @default.
• W2022878833 hasAuthorship W2022878833A5001427765 @default.
• W2022878833 hasAuthorship W2022878833A5002669383 @default.
• W2022878833 hasAuthorship W2022878833A5028848967 @default.
• W2022878833 hasAuthorship W2022878833A5030449236 @default.
• W2022878833 hasAuthorship W2022878833A5036246396 @default.
• W2022878833 hasAuthorship W2022878833A5056613332 @default.
• W2022878833 hasAuthorship W2022878833A5061673504 @default.
• W2022878833 hasAuthorship W2022878833A5068758746 @default.
• W2022878833 hasAuthorship W2022878833A5072551893 @default.
• W2022878833 hasAuthorship W2022878833A5083524146 @default.
• W2022878833 hasAuthorship W2022878833A5085672493 @default.
• W2022878833 hasAuthorship W2022878833A5091022089 @default.
• W2022878833 hasConcept C118487528 @default.
• W2022878833 hasConcept C126322002 @default.
• W2022878833 hasConcept C141071460 @default.
• W2022878833 hasConcept C168563851 @default.
• W2022878833 hasConcept C203092338 @default.
• W2022878833 hasConcept C2776403814 @default.
• W2022878833 hasConcept C2776694085 @default.
• W2022878833 hasConcept C2777288759 @default.
• W2022878833 hasConcept C2777802072 @default.
• W2022878833 hasConcept C2778257484 @default.
• W2022878833 hasConcept C2781359195 @default.
• W2022878833 hasConcept C71924100 @default.
• W2022878833 hasConceptScore W2022878833C118487528 @default.
• W2022878833 hasConceptScore W2022878833C126322002 @default.
• W2022878833 hasConceptScore W2022878833C141071460 @default.
• W2022878833 hasConceptScore W2022878833C168563851 @default.
• W2022878833 hasConceptScore W2022878833C203092338 @default.
• W2022878833 hasConceptScore W2022878833C2776403814 @default.
• W2022878833 hasConceptScore W2022878833C2776694085 @default.
• W2022878833 hasConceptScore W2022878833C2777288759 @default.
• W2022878833 hasConceptScore W2022878833C2777802072 @default.
• W2022878833 hasConceptScore W2022878833C2778257484 @default.
• W2022878833 hasConceptScore W2022878833C2781359195 @default.
• W2022878833 hasConceptScore W2022878833C71924100 @default.
• W2022878833 hasIssue "6" @default.

• next